1-[3-(4-氯苯基)-5-甲基异恶唑-4-基]乙-1-酮 | 169814-48-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-[3-(4-氯苯基)-5-甲基异恶唑-4-基]乙-1-酮
• 中文别名: 1-[3-(4-氯苯基)-5-甲基异噁唑-4-基]乙烷-1-酮
• 英文名称: 1-(3-(4-chlorophenyl)-5-methylisoxazol-4-yl)ethanone
• 英文别名: 4-acetyl-5-methyl-3-(4-chlorophenyl)isoxazole；1-[3-(4-Chlorophenyl)-5-Methylisoxazol-4-Yl]Ethan-1-One；1-[3-(4-chlorophenyl)-5-methyl-1,2-oxazol-4-yl]ethanone
• CAS: 169814-48-6
• 化学式: C₁₂H₁₀ClNO₂
• mdl: MFCD01313507
• 分子量: 235.67
• InChiKey: XSAMMAPYCPHHKH-UHFFFAOYSA-N

物化性质

• 熔点：
  54-56
• 沸点：
  385.4±42.0 °C(Predicted)
• 密度：
  1.237±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2934999090

SDS

Name:	1-[3-(4-Chlorophenyl)-5-methylisoxazol-4-y l]ethan-1-one 97% Material Safety Data Sheet
Synonym:	4-Acetyl-3-(4-chlorophenyl)-5-methylisoxazol
CAS:	169814-48-6

Section 1 - Chemical Product MSDS Name:1-[3-(4-Chlorophenyl)-5-methylisoxazol-4-y l]ethan-1-one 97% Material Safety Data Sheet
Synonym:4-Acetyl-3-(4-chlorophenyl)-5-methylisoxazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
169814-48-6	1-[3-(4-Chlorophenyl)-5-methylisoxazol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 169814-48-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 54 - 56 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H10ClNO2
Molecular Weight: 236

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, hydrogen cyanide, carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 169814-48-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-[3-(4-Chlorophenyl)-5-methylisoxazol-4-yl]ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 169814-48-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 169814-48-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 169814-48-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-[3-(4-氯苯基)-5-甲基异恶唑-4-基]乙-1-酮 以 1,4-二氧六环 为溶剂， 反应 5.5h， 生成 [3-(4-chlorophenyl)-5-methyl-1,2-oxazol-4-yl][1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl]methanone
  参考文献：
  名称：

  β-偶氮基和β-偶氮羰基烯胺的合成及其与芳族叠氮化物的反应

  摘要：

  据报道，合成了4-乙酰基取代的唑（1,2,3-三唑，1,2,3-噻二唑和1,2-恶唑）。4-乙酰基1,2,3-三唑与芳基叠氮化物的有机催化反应用于获得含有直接连接的环系统的双1,2,3-三唑。4-乙酰基唑与DMF-DMA的反应导致烯胺的形成。发现4-乙酰基-5-甲基-1,2,3-噻二唑中的乙酰基和甲基竞争反应位点的作用。获得的烯胺与叠氮化物芳基反应，形成通过羰基连接的双环杂环。合成的化合物的结构通过NMR光谱，质谱和X射线结构分析证明。

  DOI：

  10.1007/s10593-019-02525-2
• 作为产物：
  描述：

  4-chlorobenzaldoxime 在 chloroamine-T 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 6.03h， 生成 1-[3-(4-氯苯基)-5-甲基异恶唑-4-基]乙-1-酮
  参考文献：
  名称：

  A NOVEL SYNTHESIS OF ISOXAZOLES VIA 1,3-DIPOLAR CYCLOADDITION OF NITRILE OXIDES TO ACETYL ACETONE

  摘要：

  Nitrile oxides (2) isolated from the oxidative dehydrogenation of aldoximes (1) by chloramines-T react with acetyl acetone (3) to afford 4-acetyl-3-aryl-5-methyl isoxazoles (5) in good yield. All new compounds were characterized by IR, H-1 NMR, C-13 NMR, MS studies and elemental analysis.

  DOI：

  10.1081/scc-120004066

文献信息

• [EN] BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE<br/>[FR] DERIVES DE L'IMIDAZOLE BICYCLIQUES DIRIGES CONTRE LES FLAVIVIRIDAE
  申请人：GENELABS TECH INC

  公开号：WO2005012288A1

  公开（公告）日：2005-02-10

  Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

  揭示了用于治疗黄病毒科病毒感染的化合物、组合物和方法。
• Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
  申请人：Altenbach J. Robert

  公开号：US20050272728A1

  公开（公告）日：2005-12-08

  Compounds of formula (I) wherein R 1 or R 2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L 2 and L 3 , to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, L 2 , and L 3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  式（I）的化合物，其中R1或R2是直接连接或通过连接物连接的芳香或非芳香环，如由L2和L3表示，连接到杂环核心，以及X、X'、Y、Y'、Z、Z'、R1、R2、R3、R3a、R3b、R4、R5、L、L2和L3如本文所定义，可用于治疗由组胺-3受体配体预防或改善的病症或疾病。还公开了包含组胺-3受体配体的药物组合物，使用这类化合物和组合物的方法，以及制备符合式（I）范围内化合物的方法。
• Catalyst- and solvent-free mechanochemical synthesis of isoxazoles from N-hydroxybenzimidoyl chlorides and enamino carbonyl compounds
  作者：Hui Xu、Guang-Peng Fan、Zi Liu、Guan-Wu Wang

  DOI：10.1016/j.tet.2018.09.044

  日期：2018.11

  A regioselective, solvent-free and catalyst-free synthesis of isoxazoles has been successfully developed under ball milling conditions. Milling the mixtures of N-hydroxybenzimidoyl chlorides and enamino carbonyl compounds in a ball mill at a frequency of 14.6 Hz for 20–60 min afforded isoxazoles in up to 86% yields. A possible reaction mechanism leading to the formation of the observed isoxazoles is

  在球磨条件下，已成功开发了区域选择性，无溶剂和无催化剂的异恶唑合成方法。在球磨机中以14.6 Hz的频率将N-羟基苯甲酰氯和烯氨基羰基化合物的混合物研磨20-60分钟，得到的异恶唑的收率高达86％。提出了导致观察到的异恶唑形成的可能的反应机理。
• [EN] BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS<br/>[FR] AMINES À SUBSTITUTION BICYCLIQUE AYANT DES SUBSTITUANTS MONOCYCLIQUES À SUBSTITUTION CYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2005113551A1

  公开（公告）日：2005-12-01

  Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X', Y, Y', Z, Z', R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  公式（I）的化合物中，其中R1或R2是芳香或非芳香环，直接连接或通过连接剂L2和L3连接到杂环芳香核心，而X，X'，Y，Y'，Z，Z'，R1，R2，R3，R3a，R3b，R4，R5，L，L2和L3如本文所定义，可用于治疗由组胺-3受体配体预防或改善的疾病或症状。还公开了包含组胺-3受体配体的制药组合物，使用这些化合物和组合物的方法，以及制备公式（I）范围内的化合物的方法。
• Bicyclic heteroaryl derivatives
  申请人：Schmitz Ulrich Franz

  公开号：US20050187390A1

  公开（公告）日：2005-08-25

  Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

  本发明涉及用于治疗黄病毒科病毒感染的化合物、组合物和方法。